Boise and Meridian, Idaho About Glossary Questions Questions about an appointment? (208) 706-4650
Shelley K. Perkins, MD Breast Surgery

Home › Diagnosis and treatment › DCIS, stage 0

Diagnosis & treatment

DCIS, stage 0

Ductal carcinoma in situ is breast cancer at its earliest possible point: abnormal cells inside the milk ducts that have not grown through the duct wall. Because they have not, they cannot reach the lymph nodes or the rest of the body. It is treated to keep it that way.

What DCIS is

, ductal carcinoma , is breast cancer at its earliest possible point. The abnormal cells are inside the milk ducts and have not grown through the duct wall. Because they have not, they cannot reach the lymph nodes or the rest of the body. It is nearly always found on a mammogram as a cluster of tiny rather than felt as a lump. It is treated to stop it from becoming an invasive cancer later, and treatment succeeds at that for the great majority of people.

What usually happens next with DCIS, in order

  1. Measuring it. The extent on the mammogram matters more than for most cancers, because it decides whether a lumpectomy can remove all of it with a clear edge. Sometimes an MRI is added.
  2. Surgery. A if the area is small enough relative to the breast, or a if it is widespread or if you prefer it. For DCIS the pathologist wants a of at least 2 millimeters of normal tissue around it, and a second operation to widen the margin is sometimes needed.
  3. Lymph nodes. Not usually checked with a lumpectomy, because DCIS does not spread to them. Dr. Perkins does not usually do a at the time of a mastectomy either. Instead a tracer can be placed that maps the lymph nodes, so that the nodes can still be checked later if invasive cancer turns up on the final pathology report. Not every surgeon works this way, so ask yours what is planned for you.
  4. Radiation. Usually recommended after a lumpectomy, to lower the chance of DCIS or invasive cancer returning in that breast. For some small, low-grade DCIS it may be reasonable to skip it. Not needed after a mastectomy.
  5. An anti-estrogen pill. If the DCIS is estrogen receptor positive, five years of or an may be offered. It lowers the chance of a new cancer in either breast. It is optional, and many people weigh it against side effects.

is not used for DCIS, and HER2 testing is not usually done on it.

Choices you will be asked about with DCIS

Lumpectomy plus radiation, or mastectomy. For those who have the choice, the chance of the cancer coming back somewhere else in the body is the same either way. Whether to take the pill afterward. If a mastectomy, whether to , and when.

In Dr. Perkins’ own words

“Even though DCIS is noninvasive, the diagnosis is based on a biopsy, which is only a small portion of what is sometimes much more extensive disease. It is difficult to tell by the biopsy or by the imaging if there is more DCIS or more invasive cancer. I recommend treating DCIS aggressively for these reasons.”

In plain terms

DCIS is cancer that has not learned to travel. Treatment is about making sure it never does.

Questions to bring to your appointment

These are built for DCIS. The report decoder narrows the list further from your own report, and the print button there puts it on paper with room to write. Bring someone with you if you can; two sets of ears hear more than one.

Where this comes from

Sources, checked 9 September 2026

This page is written in plain language from the current NCCN Guidelines for Patients: Invasive Breast Cancer (2026 edition, based on NCCN Guidelines for Breast Cancer version 2.2026), which Dr. Perkins shared as the reference for this page and which is free to read at NCCN.org/patientguidelines, along with NCCN's separate patient guides for DCIS and for metastatic breast cancer. NCCN's material is copyrighted and nothing here reproduces it; readers who want the full detail should go to the source. Breastcancer.org publishes a free guide to reading a pathology report, updated June 2026, at breastcancer.org/pathology-report. Margin definitions follow the Society of Surgical Oncology and American Society for Radiation Oncology consensus statements for invasive cancer (2014) and DCIS (2016). Receptor cutoffs follow the American Society of Clinical Oncology and College of American Pathologists guidelines. Staging follows the American Joint Committee on Cancer, eighth edition. Every clinical statement on this page is listed on the site's verification ledger, and Dr. Perkins read the site on 13 September 2026.

This page is education. It does not diagnose, and the summary it builds is not a treatment plan. Your plan is made with your own care team from your own results.

Published 7 September 2026 as part of the guide; a page of its own since 9 September 2026; reviewed by Dr. Perkins 13 September 2026, whose own wording on lymph nodes and on how she treats DCIS was added the same day and revised by her on 14 September 2026.

Call the office